Condition

Multiple Myeloma, Newly Diagnosed clinical trials and research

• 6Clinical trials
• 5Countries

Newest Multiple Myeloma, Newly Diagnosed clinical trials

All recruiting trials (6)

• MRD‑guided BCMA CAR-T with optional GPRC5D/CD3 BiTE consolidation for transplant‑ineligible newly diagnosed multiple myeloma

  This trial will try MRD‑guided immunotherapy using BCMA CAR‑T for adults newly diagnosed with multiple myeloma who cannot have a transplant, adding a GPRC5D/CD3 bispecific antibody for those at very high risk.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07106736

• High‑dose transplant with BCMA CAR‑T followed by GPRC5D/CD3 bispecific antibody maintenance for ultra‑high‑risk newly diagnosed multiple myeloma

  This trial will test whether combining autologous stem‑cell transplant, BCMA CAR‑T cells, and GPRC5D/CD3 bispecific antibody maintenance helps people under 70 with newly diagnosed ultra‑high‑risk multiple myeloma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07106710

• Frontline T-cell engager plus daratumumab versus autologous stem cell transplant with MRD-guided intensification for newly diagnosed multiple myeloma

  This trial tests whether a BCMA-directed T-cell engager (elranatamab) combined with daratumumab can replace autologous stem cell transplant and use MRD results to guide later intensification in adults with newly diagnosed multiple myeloma who already completed standard induction therapy.

  Recruiting at 10 sites Phase 2 SCRI Development Innovations, LLC · Birmingham, Alabama and 10 other locations · NCT06974786

• Elranatamab plus lenalidomide after D-VRd and transplant for transplant-eligible newly diagnosed multiple myeloma

  This trial will test whether adding elranatamab with lenalidomide after D-VRd induction and transplant, and using elranatamab for maintenance, helps people with newly diagnosed, transplant-eligible multiple myeloma stay in remission longer than standard lenalidomide.

  Recruiting at 64 sites Phase 3 Intergroupe Francophone du Myelome · Brussels and 68 other locations · NCT06918002

• Consolidation therapy for newly diagnosed multiple myeloma after transplant

  This study is testing if a combination treatment after a stem cell transplant can help people with newly diagnosed multiple myeloma have better outcomes and stay in remission longer.

  Recruiting at 3 sites Phase 2/3 Peking University People's Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06879379

• Low-dose teclistamab for newly diagnosed multiple myeloma patients

  This study tests if a low dose of teclistamab can help newly diagnosed multiple myeloma patients stay in remission after initial treatment.

  Recruiting Phase 2 Hospital Universitario Dr. Jose E. Gonzalez · Monterrey, Nuevo León · NCT06758375

Related topics

Quick answers

How many Multiple Myeloma, Newly Diagnosed clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (3 trials), United States (1 trial), Belgium (1 trial), France (1 trial), Mexico (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 3: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →